Kura Oncology Inc at Bank of America Merrill Lynch Health Care Conference Transcript
My name is Ying Huang. I'm the senior biotech analyst here at Bank of America Merrill Lynch. And welcome to the first day of BofA Merrill Healthcare Conference. And I'm very pleased to announce the next presenting company, Kura Oncology. We have Troy Wilson. Dr. Wilson is the President and CEO of Kura. With that, let me welcome Dr. Troy.
Good afternoon, everyone. Thank you, Ying, for the introduction, and thanks to Bank of America Merrill Lynch for the invitation to present. As mentioned, I'm Troy Wilson, the President and CEO Kura Oncology. I'll be making certain forward-looking statements, and I refer you to the SEC's website or our website for additional information on the company.
Kura is a precision medicine company advancing a pipeline of targeted therapeutics. We have multiple assets in our portfolio, including 3 programs shown here from left to right: tipifarnib; which is our farnesyl
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |